Premium
Aberrant expression of caspase 14 in salivary gland carcinomas
Author(s) -
Lemound Juliana,
StuckiKoch Angelika,
Stoetzer Marcus,
Kokemüller Horst,
Gellrich NilsClaudius,
Kreipe Hans,
Hussein Kais
Publication year - 2015
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/jop.12253
Subject(s) - salivary gland , immunohistochemistry , pathology , biology , caspase 3 , mucin , cancer research , apoptosis , medicine , programmed cell death , biochemistry
Objectives Caspase 14 is reduced in adenocarcinomas of the stomach and colon. In contrast, breast and lung adenocarcinomas frequently show an overexpression of caspase 14. Salivary gland adenocarcinomas have not been evaluated for potential aberrant caspase 14 expression. Materials and Methods Samples from salivary gland carcinomas ( n = 43) were analysed by immunohistochemistry (caspase 14, filaggrin, GATA 3 and Ki67) and fluorescence in situ hybridization. Results Caspase 14 is not expressed in normal salivary glands, while in a subfraction of carcinomas (32%) an aberrant expression was found. Filaggrin could not be detected. Caspase 14 staining was not associated with tumour dedifferentiation, GATA 3 expression or amplification of gene locus 19p13. Conclusion In summary, aberrant expression of caspase 14 can be found in a subfraction of salivary gland carcinomas but could not be used as a biomarker for a specific carcinoma subtype of the salivary gland.